Literature DB >> 27092430

Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012.

Matthew S Chang1, Kerri Barton, Molly Crockett, Ruth E Tuomala, Anna E Rutherford, Muthoka L Mutinga, Karin L Andersson, Robert S Brown, Emily Oken, Chinweike Ukomadu.   

Abstract

GOALS: To determine postpartum hepatitis B virus (HBV) laboratory testing rates and identify factors associated with a lack of follow-up testing in Massachusetts.
BACKGROUND: Screening for HBV infection in pregnant women is standard of care. Guidelines recommend that patients with chronic HBV have ongoing care and laboratory testing, but little is known about postpartum maternal HBV care outcomes. STUDY: We conducted a retrospective cohort study using Massachusetts Virtual Epidemiologic Network, an electronic public health surveillance system maintained by the Massachusetts Department of Public Health. We identified women who tested hepatitis B surface antigen positive during their first reported (index) pregnancy in Massachusetts from 2007 to 2012 and measured HBV-related laboratory tests reported to Massachusetts Department of Public Health during and after pregnancy.
RESULTS: We identified 983 hepatitis B surface antigen positive pregnant women. Half (492/983) did not have evidence of additional postpartum HBV laboratory testing following their index pregnancy. Women who had postpartum laboratory tests reported were younger [mean age (SD): 29 (5.3) vs. 31 (5.5) y, P=0.0001] and more likely to have >1 pregnancy during the study period (41% vs. 1%, P<0.0001). There were no differences in race, ethnicity, and US born status. On multivariable logistic regression, older age predicted a lower likelihood of having postpartum laboratory testing (odds ratio, 0.77; 95% confidence interval, 0.70-0.90).
CONCLUSIONS: Postpartum maternal HBV follow-up laboratory testing occurred in only half of Massachusetts women and did not vary by race, ethnicity, or US born status. Our results were limited to a single state surveillance database, which likely underestimates the number of tests ordered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27092430      PMCID: PMC4899286          DOI: 10.1097/MCG.0000000000000530

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

1.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.

Authors:  J J Ott; G A Stevens; J Groeger; S T Wiersma
Journal:  Vaccine       Date:  2012-01-24       Impact factor: 3.641

2.  A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.

Authors:  Eric E Mast; Harold S Margolis; Anthony E Fiore; Edward W Brink; Susan T Goldstein; Susan A Wang; Linda A Moyer; Beth P Bell; Miriam J Alter
Journal:  MMWR Recomm Rep       Date:  2005-12-23

3.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

4.  Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission.

Authors:  Elizabeth Ramsey Unal; Gweneth B Lazenby; Anne E Lintzenich; Kit N Simpson; Roger Newman; Laura Goetzl
Journal:  Obstet Gynecol       Date:  2011-09       Impact factor: 7.661

5.  Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis.

Authors:  Unzila A Nayeri; Erika F Werner; Christina S Han; Christian M Pettker; Edmund F Funai; Stephen F Thung
Journal:  Am J Obstet Gynecol       Date:  2012-06-11       Impact factor: 8.661

6.  Antiviral therapy for chronic hepatitis B in pregnancy.

Authors:  Calvin Q Pan; Hannah M Lee
Journal:  Semin Liver Dis       Date:  2013-06-08       Impact factor: 6.115

7.  Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.

Authors:  Robert S Brown; Elizabeth C Verna; Marcus R Pereira; Hugh H Tilson; Christopher Aguilar; Cheng-Shiun Leu; Maria Buti; Elizabeth A Fagan
Journal:  J Hepatol       Date:  2012-07-02       Impact factor: 25.083

8.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Christy Wing-Hin Mak; Stanley King-Yeung Lee; Zoe Man-Yi Ip; Andrew Ting-Ho Lam; Henry Wing-Hang Iu; Joyce May-Sum Leung; Jennifer Wing-Yan Lai; Angeline Oi-Shan Lo; Hoi-Yun Chan; Vincent Wai-Sun Wong
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

9.  Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

Authors:  Young-Suk Lim; Seungbong Han; Nae-Yun Heo; Ju Hyun Shim; Han Chu Lee; Dong Jin Suh
Journal:  Gastroenterology       Date:  2014-02-25       Impact factor: 22.682

10.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

Authors:  Astrid-Jane Greenup; Pok Kern Tan; Vi Nguyen; Anne Glass; Scott Davison; Ushmi Chatterjee; Susan Holdaway; Dev Samarasinghe; Kathy Jackson; Stephen A Locarnini; Miriam T Levy
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

View more
  3 in total

1.  Peripartum Care for Mothers Diagnosed with Hepatitis B During Pregnancy: A Survey of Provider Practices.

Authors:  Allison J Kwong; Matthew S Chang; Ruth E Tuomala; Laura E Riley; Julian N Robinson; Muthoka L Mutinga; Karin L Andersson; Robert S Brown; Emily Oken; Chinweike Ukomadu; Anna E Rutherford
Journal:  Matern Child Health J       Date:  2018-09

2.  Surveillance-Based Estimate of the Prevalence of Chronic Hepatitis B Virus Infection, New York City, 2016.

Authors:  Miranda S Moore; Angelica Bocour; Ann Winters
Journal:  Public Health Rep       Date:  2019-10-24       Impact factor: 2.792

3.  Peripartum Maternal Hepatitis B Care in a US Nationwide Data Set.

Authors:  Matthew S Chang; J Frank Wharam; Fang Zhang; Robert F LeCates; Emma Morton-Eggleston; Ruth E Tuomala; Anna E Rutherford; Muthoka L Mutinga; Karin L Andersson; Robert S Brown; Chinweike Ukomadu; Emily Oken
Journal:  J Clin Gastroenterol       Date:  2019 Nov/Dec       Impact factor: 3.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.